Phase 3 Extension Study of Dexpramipexole in ALS

Summary

The purpose of the study is to collect long-term safety data from subjects with Amyotrophic Lateral Sclerosis (ALS) exposed to dexpramipexole.

Timeline

Start

2012-06

Primary completion

2013-02

Completion

2013-02

Outcome

Outcome not reported

Stopped: “The Initial Phase 3 Study (NCTO1281189) did not meet its primary efficacy endpoint.”

Drugs

Indications